Sinoway Industrial Co., Ltd.

Gliclazide 21187-98-4 Gliclazide 21187-98-4

Gliclazide 21187-98-4
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Gliclazide :

Name

Gliclazide

Alias

1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea ;benzenesulfonamide,n-(((hexahydrocyclopenta(c)pyrrol-2(1h)-yl)amino)carbonyl ;n-(4-methylbenzenesulfonyl)-n’-(3-azabicyclo(3.3.0)oct-3-yl)urea ;s852 ;se1702

CAS NO.

21187-98-4

Molecular Formula

C15H21N3O3S

Molecular Weight

323.41

Brief Introduction

Gliclazide is a sulfonylurea oral anti-diabetic drug


Use of Gliclazide:

Gliclazide is the second generation oral sulphonylurea hypoglycemic agent, which has a stronger effect. Its mechanism is similar to tolbutamide, that is, it selectively acts on islet β cells, promotes insulin secretion, and improves insulin after glucose intake. freed. Its role is more than 10 times stronger than tolbutamide. In recent years, it has also been found that gliclazide has an extrapancreatic effect, which enhances the effect of peripheral tissues on insulin. It may be the result of enhanced biological effects after insulin receptors. At the same time, hepatic glucose production and output are also resisted, so that gliclazide has a post-pancreatic receptor or receptor. Another view is that sulfonylureas increase the number of insulin receptors in target tissues and increase the sensitivity of peripheral target tissues to insulin. Glieszide has been proven to reduce platelet aggregation and adhesion by animal experiments and clinical use, and prevent the deposition of the albumin on the microvascular wall, which has a preventive and therapeutic effect on diabetic microangiopathy. Animal experiments have shown that long-term use of gliclazide can significantly reduce liver cholesterol, lower triacylglycerols and fatty acids. Histological examinations show that it can resist the damage of arteries, especially coronary arteries, caused by high cholesterol foods, and it is beneficial to reduce the cardiovascular complications of diabetes.

COA of Gliclazide :

Test

Requirement

Result

Appearance

White or almost white powder

White powder

Identification/IR

Corresponding to reference spectrum

Corresponding to reference spectrum

Related  substances

Impurity F

≤0.1%

0.02%


Unspecified impurities

≤0.10%

0.04%


Sum of impurities other than F

≤0.2%

0.04%

Impurity B

≤2ppm

0.4ppm

Heavy metals

≤10ppm

<10ppm

Loss on drying

≤0.25%

0.12%

Sulphated ash

≤0.1%

<0.05%

Assay (dried substance)

99.0~101.0%

99.2%

CONCLUSION

CONFORM WITH BP2017.



  • Dasatinib 302962-49-8
    Basic information of Dasatinib :Name Dasatinib CAS NO.302962-49-8Molecular FormulaC22H28CIN7O3SQuality StandardUSP26, EP VIDocumentsGMP, DMFPackage SizeAluminium bag;Brief IntroductionAuxiliaries and ... Dasatinib 302962-49-8
  • Olmesartan Medoxomil 144689-63-4/144689-78-1
    Basic information of Olmesartan Medoxomil:NameOlmesartan MedoxomilMolecular FormulaC24H26N6O3Molecular Weight446.5Quality StandardI.H.SPackage Size25kg/drumBrief IntroductionOlmesartan medoxomil is an... Olmesartan Medoxomil 144689-63-4/144689-78-1
  • Spironolactone 52-01-7
    Basic informationProduct Name: Spironolactone Molecular Formula : C24H32O4SMolecular Weight: 416.57CAS No.: 52-01-7Appearance: White powderSpecifications:EP8/USP38UsagesTreat for High blood pressureTreat ... Spironolactone 52-01-7
  • Metformin 657-24-9
    Basic information of Metformin:NameMetforminMolecular FormulaC4H11N5Molecular Weight129.16Quality StandardEP/USP/BPPackage Size25kg/drumBrief IntroductionMetformin, marketed under the tradename Glucop... Metformin 657-24-9

MORE_DETAIL Gliclazide 21187-98-4

Basic information of Gliclazide :

Name

Gliclazide

Alias

1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea ;benzenesulfonamide,n-(((hexahydrocyclopenta(c)pyrrol-2(1h)-yl)amino)carbonyl ;n-(4-methylbenzenesulfonyl)-n’-(3-azabicyclo(3.3.0)oct-3-yl)urea ;s852 ;se1702

CAS NO.

21187-98-4

Molecular Formula

C15H21N3O3S

Molecular Weight

323.41

Brief Introduction

Gliclazide is a sulfonylurea oral anti-diabetic drug


Use of Gliclazide:

Gliclazide is the second generation oral sulphonylurea hypoglycemic agent, which has a stronger effect. Its mechanism is similar to tolbutamide, that is, it selectively acts on islet β cells, promotes insulin secretion, and improves insulin after glucose intake. freed. Its role is more than 10 times stronger than tolbutamide. In recent years, it has also been found that gliclazide has an extrapancreatic effect, which enhances the effect of peripheral tissues on insulin. It may be the result of enhanced biological effects after insulin receptors. At the same time, hepatic glucose production and output are also resisted, so that gliclazide has a post-pancreatic receptor or receptor. Another view is that sulfonylureas increase the number of insulin receptors in target tissues and increase the sensitivity of peripheral target tissues to insulin. Glieszide has been proven to reduce platelet aggregation and adhesion by animal experiments and clinical use, and prevent the deposition of the albumin on the microvascular wall, which has a preventive and therapeutic effect on diabetic microangiopathy. Animal experiments have shown that long-term use of gliclazide can significantly reduce liver cholesterol, lower triacylglycerols and fatty acids. Histological examinations show that it can resist the damage of arteries, especially coronary arteries, caused by high cholesterol foods, and it is beneficial to reduce the cardiovascular complications of diabetes.

COA of Gliclazide :

Test

Requirement

Result

Appearance

White or almost white powder

White powder

Identification/IR

Corresponding to reference spectrum

Corresponding to reference spectrum

Related  substances

Impurity F

≤0.1%

0.02%


Unspecified impurities

≤0.10%

0.04%


Sum of impurities other than F

≤0.2%

0.04%

Impurity B

≤2ppm

0.4ppm

Heavy metals

≤10ppm

<10ppm

Loss on drying

≤0.25%

0.12%

Sulphated ash

≤0.1%

<0.05%

Assay (dried substance)

99.0~101.0%

99.2%

CONCLUSION

CONFORM WITH BP2017.


Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//